{"id":158,"date":"2019-07-16T00:08:04","date_gmt":"2019-07-16T00:08:04","guid":{"rendered":"http:\/\/clladvocates.phillipsandphillips.nz\/?page_id=158"},"modified":"2019-08-13T21:58:21","modified_gmt":"2019-08-13T21:58:21","slug":"research","status":"publish","type":"page","link":"https:\/\/clladvocates.nz\/?page_id=158","title":{"rendered":"Research"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;2&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; bottom_divider=&#8221;step&#8221;][vc_column column_width_percent=&#8221;100&#8243; position_horizontal=&#8221;left&#8221; position_vertical=&#8221;middle&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]Research and reports[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;2&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; bottom_divider=&#8221;step&#8221;][vc_column column_width_percent=&#8221;100&#8243; position_horizontal=&#8221;left&#8221; position_vertical=&#8221;middle&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_icon position=&#8221;left&#8221; icon_image=&#8221;514&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; linked_title=&#8221;yes&#8221; title=&#8221;International comparisons of modern medicine&#8221; link=&#8221;url:https%3A%2F%2Fwww.medicinesnz.co.nz%2Ffileadmin%2Fuser_upload%2FIQVIA_ICOMM_Report__August_2019___1_.pdf|||&#8221; link_text=&#8221;Download&#8221;]This report was commissioned by Medicines New Zealand and reviews the public funding of highly innovative modern medicines across eight key therapy areas including cancer, and compares medicine reimbursement within 20 OECD countries between 2011-2017 inclusive.[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Overview of the treatment of CLL&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Foverview-of-the-treatment-of-chronic-lymphocytic-leukemia|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin.[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Clinical features and diagnosis of CLL\/small lymphocytic lymphoma&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Fclinical-features-and-diagnosis-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) is a mature B cell neoplasm characterized by a progressive accumulation of monoclonal B lymphocytes.[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Overview of the complications of CLL&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Foverview-of-the-complications-of-chronic-lymphocytic-leukemia|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of usually monoclonal, functionally incompetent lymphocytes. Patients with CLL commonly develop complications associated with the intrinsic immune dysfunction that results in immunodeficiency and the development of autoimmune disorders.[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Staging and prognosis of CLL&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Fstaging-and-prognosis-of-chronic-lymphocytic-leukemia|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia (CLL) is one of the B cell chronic lymphoproliferative disorders (lymphoid neoplasms). According to the World Health Organization classification, B cell CLL is considered to be identical (ie, one disease with different manifestations) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma&#8230;[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Selection of initial therapy for symptomatic or advanced CLL&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Fselection-of-initial-therapy-for-symptomatic-or-advanced-chronic-lymphocytic-leukemia|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.[\/vc_icon][vc_separator][vc_icon position=&#8221;left&#8221; icon_image=&#8221;509&#8243; media_size=&#8221;150&#8243; text_size=&#8221;h4&#8243; add_margin=&#8221;yes&#8221; title=&#8221;Treatment of relapsed or refractory CLL&#8221; link=&#8221;url:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Ftreatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia|||&#8221; link_text=&#8221;Read more&#8221;]Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin.[\/vc_icon][vc_separator][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;2&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; bottom_divider=&#8221;step&#8221;][vc_column column_width_percent=&#8221;100&#8243; position_horizontal=&#8221;left&#8221; position_vertical=&#8221;middle&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; shift_x=&#8221;0&#8243; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":151,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-158","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=158"}],"version-history":[{"count":25,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/158\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/158\/revisions\/524"}],"up":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/pages\/151"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}